Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia:: Implications for mutation detection in peripheral blood

被引:14
作者
Stevenson, William S.
Hoyt, Rosemary
Bell, Anthony
Guipponi, Michel
Juneja, Surender
Grigg, Andrew P.
Curtis, David J.
Scott, Hamish S.
Szer, Jeff
Alexander, Warren S.
Tuckfield, Annabel
Roberts, Andrew W.
机构
[1] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia
[2] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
关键词
myeloproliferative disorder; essential thrombocythaemia; thrombocytosis;
D O I
10.1080/00313020600820906
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
Aims: The molecular pathogenesis of essential thrombocythaemia ( ET) is heterogeneous. We aimed to determine the relative sensitivity of four separate molecular assays used to detect the presence of the JAK2 V617F mutation in peripheral blood from patients with essential thrombocythaemia and related myeloproliferative disorders. Methods: Purified granulocytes from 60 patients were analysed for the presence of the JAK2 V617F mutation by direct sequencing, denaturing high-performance liquid chromatography ( DHPLC), allele-specific polymerase chain reaction ( PCR) and allele- specific enrichment. Clinical data were collected for all patients and correlated with assay results. Results: Direct sequencing and DHPLC were relatively insensitive assays for mutation detection, together identifying only 53% of the JAK2 V617F positive cases of ET. Allelespecific PCR and allele- specific enrichment were significantly more sensitive assays and were able to identify additional ET patients that were positive for the JAK2 V617F mutation in only a minority of circulating granulocytes. Enrichment for the mutation was demonstrated in blood platelets from two of these patients. Conclusions: The observed biological difference in circulating granulocyte involvement by the JAK2 V617F clone necessitates a sensitive molecular assay for the diagnostic investigation of thrombocytosis.
引用
收藏
页码:336 / 342
页数:7
相关论文
共 15 条
[1]
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia [J].
Antonioli, E ;
Guglielmelli, P ;
Pancrazzi, A ;
Bogani, C ;
Verrucci, M ;
Ponziani, V ;
Longo, G ;
Bosi, A ;
Vannucchi, AM .
LEUKEMIA, 2005, 19 (10) :1847-1849
[2]
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[3]
Clonality analysis of hematopoiesis in essential thrombocythemia: Advantages of studying T lymphocytes and platelets [J].
ElKassar, N ;
Hetet, G ;
Briere, J ;
Grandchamp, B .
BLOOD, 1997, 89 (01) :128-134
[4]
A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications [J].
Harrison, CN ;
Gale, RE ;
Machin, SJ ;
Linch, DC .
BLOOD, 1999, 93 (02) :417-424
[5]
Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3
[6]
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].
James, C ;
Ugo, V ;
Le Couédic, JP ;
Staerk, J ;
Delhommeau, F ;
Lacout, C ;
Garçon, L ;
Raslova, H ;
Berger, R ;
Bennaceur-Griscelli, A ;
Villeval, JL ;
Constantinescu, SN ;
Casadevall, N ;
Vainchenker, W .
NATURE, 2005, 434 (7037) :1144-1148
[7]
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J].
Jones, AV ;
Kreil, S ;
Zoi, K ;
Waghorn, K ;
Curtis, C ;
Zhang, LY ;
Score, J ;
Seear, R ;
Chase, AJ ;
Grand, FH ;
White, H ;
Zoi, C ;
Loukopoulos, D ;
Terpos, E ;
Vervessou, EC ;
Schultheis, B ;
Emig, M ;
Ernst, T ;
Lengfelder, E ;
Hehlmann, R ;
Hochhaus, A ;
Oscier, D ;
Silver, RT ;
Reiter, A ;
Cross, NCP .
BLOOD, 2005, 106 (06) :2162-2168
[8]
A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].
Kralovics, R ;
Passamonti, F ;
Buser, AS ;
Teo, S ;
Tiedt, R ;
Passweg, JR ;
Tichelli, A ;
Cazzola, M ;
Skoda, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790
[9]
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].
Levine, RL ;
Wadleigh, M ;
Cools, J ;
Ebert, BL ;
Wernig, G ;
Huntly, BJP ;
Boggon, TJ ;
Wlodarska, L ;
Clark, JJ ;
Moore, S ;
Adelsperger, J ;
Koo, S ;
Lee, JC ;
Gabriel, S ;
Mercher, T ;
D'Andrea, A ;
Fröhling, S ;
Döhner, K ;
Marynen, P ;
Vandenberghe, P ;
Mesa, RA ;
Tefferi, A ;
Griffin, JD ;
Eck, MJ ;
Sellers, WR ;
Meyerson, M ;
Golub, TR ;
Lee, SJ ;
Gilliland, DG .
CANCER CELL, 2005, 7 (04) :387-397
[10]
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method [J].
Livak, KJ ;
Schmittgen, TD .
METHODS, 2001, 25 (04) :402-408